O’Farrell, Marie
Duke, Greg
Crowley, Richard
Buckley, Douglas
Martins, Eduardo B.
Bhattacharya, Dipankar
Friedman, Scott L.
Kemble, George
Funding for this research was provided by:
Sagimet provided funding for this work.
NIH funding (grant number 1 R01 DK128289)
Article History
Received: 6 March 2022
Accepted: 30 August 2022
First Online: 19 September 2022
Competing interests
: MOF, GK, DBu, GD, EB, RC and SF are/were employees or consultants of Sagimet Biosciences. DBh does not have competing interests. SF has the following additional disclosures, not considered conflicts; Consulting: 89 Bio, Amgen, Axcella Health, Blade Therapeutics, Bristol Myers Squibb, Can-Fite Biopharma, ChemomAb, Escient Pharmaceuticals, Forbion, Foresite laboratories, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, Hepgene, In sitro, Morphic Therapeutics, North Sea Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Scholar Rock, Surrozen. Stock options: Blade Therapeutics, Escient, Galectin Galmed, Genfit, Glympse, Hepgene, Lifemax, Metacrine, Morphic Therapeutics, Nimbus, North Sea, Therapeutics, Scholar Rock. Research Activities with Commercial Entities): Morphic Therapeutics Novo Nordisk Abalone Bio (SBIR Grant), Galmed.